MX9706964A - Uso de 8,9-deshidroestrona como un estrogeno con efectos neutros sobre los niveles de prolactina. - Google Patents

Uso de 8,9-deshidroestrona como un estrogeno con efectos neutros sobre los niveles de prolactina.

Info

Publication number
MX9706964A
MX9706964A MX9706964A MX9706964A MX9706964A MX 9706964 A MX9706964 A MX 9706964A MX 9706964 A MX9706964 A MX 9706964A MX 9706964 A MX9706964 A MX 9706964A MX 9706964 A MX9706964 A MX 9706964A
Authority
MX
Mexico
Prior art keywords
dehydroestrone
estrogen
prolactin levels
mammal
neutral effects
Prior art date
Application number
MX9706964A
Other languages
English (en)
Other versions
MXPA97006964A (es
Inventor
Andres Negro-Vilar
Michael Jay Gast
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of MX9706964A publication Critical patent/MX9706964A/es
Publication of MXPA97006964A publication Critical patent/MXPA97006964A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Esta invencion proporciona un método para proporcionar terapia o suplementacion estrogénica en un mamífero en necesidad del mismo, en donde es indeseable una elevacion en los niveles de prolactina concomitantes con dicha suplementacion estrogénica, en el mamífero, el cual comprende administrar una cantidad efectiva de la 8,9-deshiestrona o una sal farmacéuticamente aceptable de su éster de 3-sulfato a dicho mamífero.
MXPA/A/1997/006964A 1996-09-16 1997-09-12 Uso de 8,9-deshidroestrona como un estrogeno con efectos neutros sobre los niveles de prolactina MXPA97006964A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72867696A 1996-09-16 1996-09-16
US728676 1996-09-16

Publications (2)

Publication Number Publication Date
MX9706964A true MX9706964A (es) 1998-08-30
MXPA97006964A MXPA97006964A (es) 1998-11-12

Family

ID=

Also Published As

Publication number Publication date
BR9704710A (pt) 1998-12-29
HUP9701542A3 (en) 2000-01-28
EP0829263A1 (en) 1998-03-18
CZ286397A3 (cs) 1998-03-18
KR19980024568A (ko) 1998-07-06
HU9701542D0 (en) 1997-10-28
JPH10101567A (ja) 1998-04-21
ZA978305B (en) 1999-03-15
HUP9701542A2 (hu) 1998-06-29
IL121755A0 (en) 1998-02-22
AU3755397A (en) 1998-03-19
SK122897A3 (en) 1998-04-08
SG65684A1 (en) 1999-06-22
NZ328739A (en) 1999-08-30
ID18256A (id) 1998-03-19
CA2215655A1 (en) 1998-03-16

Similar Documents

Publication Publication Date Title
EP0893949A4 (en) USE OF ANTIOXIDANTS FOR TREATING CHOLESTATIC LIVER DISEASES
NZ514574A (en) Novel method of treatment
GR3033667T3 (en) Use of non-steroidal cyclooxygenase inhibitors to treat elevated intraocular pressure
AU3215597A (en) Method of inhibiting fibrosis with a somatostatin agonist
EP0744942A4 (en) HYDROGEL FORMULATION WITH CONTROLLED RELEASE
MD1699F2 (ro) Compoziţie apoasă a hormonului somatotrop uman şi procedeu de prevenire a denaturării ei
AU2959995A (en) Stereochemical wortmannin derivatives
GB9614902D0 (en) Sustained release composition
NZ323456A (en) Pharmaceutical composition of an estrogen agonist/antagonist and a prostaglandin or a prostaglandin agonist/antagonist; useful for combination therapy for osteoporosis
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
AU3218197A (en) Natural progesterone for the treatment of side effects of progestins and progesterone analogues
PL319295A1 (en) Combination of prostacycline with estrogen or progestin for preventing and treating atherosclerotic diseases, including preeclampsia and hypertension as well as for hormone substitution therapy
AU3436097A (en) Progestogen-anti-progestogen regimens
AU3382995A (en) Combined preparation for the therapy of immunological diseases
TW325996B (en) Anti-atherosclerotic composition containing 17α-dihydroequilin
MX9706964A (es) Uso de 8,9-deshidroestrona como un estrogeno con efectos neutros sobre los niveles de prolactina.
EP0910375A4 (en) COMPOSITION BASED ON ENALAPRIL AND LOSARTAN
CA2248198A1 (fr) Utilisation de n-aryl-2-hydroxyalkylamides pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
RO118794B1 (ro) Metodă de tratament a unor stări dependente de steroizii gonadici
ZA973749B (en) Transdermal administration of steroid hormones using diethanolamides of C12-C18 fatty acids as permeation enhancers.
MX9606009A (es) Uso de 8,9-deshidroestrona como un antioxidante.
AU6015794A (en) Anti-atherosclerotic agents
IL126158A0 (en) Method for treating substance abuse
AU4308699A (en) Use of anti-prolactin agents to treat proliferative conditions
RU97115759A (ru) Использование 8,9-дегидроэстрона в качестве эстрогена с нейтральными воздействиями на уровни пролактина